Merck: targets 18% to 20% sales growth in 2022

(CercleFinance.com) - Global sales reached 14.
6 billion dollars in Q2 2022, up 28% y-o-y.

Pharmaceutical sales increased 28% to 12.8 billion dollars. Pharmaceutical sales growth was 16% in Q2 for excluding LAGEVRIO sales, primarily driven by oncology, vaccines and hospital acute care products.

GAAP EPS from continuing operations was $1.55 in of 2022. Non-GAAP EPS was $1.87 for the second quarter of 2022 (versus $0.61 for the second quarter of 2021).

Merck expects sales growth of 18% to 20% in 2022, with estimated annual sales of $57.5 billion to $58.5 billion. The company also expects its full-year 2022 GAAP EPS to be between $5.89 and $5.99.

Merck is reducing its FY 2022 expected non-GAAP EPS range to between $7.25 and $7.35.


Copyright (c) 2022 CercleFinance.com. All rights reserved.